Kane Biotech Inc (TSE:KNE)
:KNE
Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.03
<C$0.01(4.76%)
At close: 4:00 PM EST
C$0.03
<C$0.01(4.76%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.07
Previous CloseN/A
Volume199.87K
Average Volume (3M)112.95K
Market Cap
C$5.46M
Enterprise ValueC$7.89M
Total Cash (Recent Filing)C$395.06K
Total Debt (Recent Filing)C$1.92M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding181,856,570
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Anti-biofilm PlatformA proprietary anti-biofilm platform targets a structural clinical and industrial problem (persistent infections, contamination). Durable demand across wound care, animal health and industrial uses supports long-term commercialization paths and provides a defensible technical moat if efficacy and regulatory progress are sustained.
Multiple Revenue Channels (products, Licensing, Partnerships)A diversified revenue model (direct product sales, licensing/royalties, partner collaborations) supports multiple monetization routes and reduces reliance on any single channel. Structurally, licensing can produce recurring royalties and partnerships can scale distribution without equivalent capital intensity, aiding longer-term resilience.
Improved Cash Burn And Reduced Debt Versus Prior PeriodsReduced leverage and a declining cash burn trajectory are durable positives for runway and financial flexibility. Improved cash discipline lowers near-term refinancing pressure and frequency of dilutive raises, enabling management to focus resources on commercialization and R&D over the coming months.
Bears Say
Sharp Revenue Collapse And Negative Gross ProfitAn ~86% TTM revenue drop and negative gross profit indicate material commercial underperformance and broken operating leverage. Persistently negative gross margin undermines the business model's sustainability and suggests core products or distribution are not generating required unit economics without structural remediation.
Negative Shareholders' Equity Limits FlexibilityNegative equity is a structural capital weakness that constrains access to non-dilutive financing and can trigger restrictive covenants. Over months, this raises the probability of dilutive capital raises or difficult refinancing, hampering strategic initiatives and partner confidence in longer-term commercialization plans.
Persistent Negative Operating And Free Cash FlowSustained negative OCF and FCF require repeated external funding to maintain operations and R&D. Over a multi-month horizon this elevates dilution risk, constrains discretionary spending on commercialization, and forces management to prioritize liquidity over strategic investments, slowing durable growth prospects.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.03 and its highest was C$0.07 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$5.46M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is Aug 27, 2026 which is in 80 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 181,856,570 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
Technical Analysis
Aptose Biosciences
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---